Within-subject evaluation of interim buprenorphine treatment during waitlist delays.

ABSTRACT:

Background

The effectiveness of opioid agonist treatment for opioid use disorder (OUD) is well established, and delays to treatment are still common, particularly in rural geographic areas. In a randomized 12-week pilot study, we demonstrated initial efficacy of a technology-assisted Interim Buprenorphine Treatment (IBT) vs. continued waitlist control (WLC) for reducing illicit opioid use and other risk behaviors during waitlist delays. Upon completion of that parent trial, WLC participants were given the opportunity to receive 12 weeks of IBT, permitting an additional within-subject examination of IBT effects.

Methods

Sixteen WLC participants crossed over to receive IBT, involving buprenorphine maintenance with bi-monthly visits, medication administration at home via a comp

SUBMITTER: Oleskowicz TN 

PROVIDER: S-EPMC8148627 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature